Testosterone Cypionate vs AndroGel: Real-World Evidence Comparison

What Are These Two Testosterone Formulations?

Testosterone cypionate is a long-chain ester of testosterone dissolved in cottonseed oil and delivered via intramuscular or subcutaneous injection. AndroGel is a hydroalcoholic gel that delivers testosterone transdermally. Both are FDA-approved for males with hypogonadism confirmed by two morning total testosterone measurements below 300 ng/dL and symptoms consistent with androgen deficiency. [1]

Testosterone Cypionate: Mechanism and Pharmacokinetics

After intramuscular injection, the cypionate ester is cleaved by plasma esterases, releasing free testosterone. Peak serum levels occur at roughly 24 to 72 hours post-injection, then decline exponentially. With a 14-day dosing interval, many patients experience trough levels that dip below 300 ng/dL, which may reproduce hypogonadal symptoms such as fatigue, reduced libido, and mood instability. [2]

Shortening the dosing interval to every 7 days (or even 3.5 days with subcutaneous micro-dosing) flattens the curve considerably. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism confirmed that weekly cypionate dosing produced a 30% reduction in peak-to-trough variability compared with biweekly administration. [3]

AndroGel: Mechanism and Pharmacokinetics

AndroGel delivers testosterone through the stratum corneum. Approximately 10% of the applied dose is absorbed systemically when applied to the shoulders, upper arms, or abdomen. Steady-state serum testosterone is reached within 24 to 72 hours and remains relatively stable day to day, provided the patient applies the gel at the same time each day and avoids showering for at least two hours afterward. [4]

The FDA-approved labeling for AndroGel 1.62% (NDA 202-439) specifies a starting dose of 40.5 mg daily, titrated based on morning serum testosterone measured 14 days after starting therapy. [5]

Efficacy: What Do the Trials Actually Show?

Both formulations normalize serum testosterone in most hypogonadal men, but the clinical outcomes that matter to patients, including bone mineral density, sexual function, and mood, show meaningful differences by delivery route in long-term data.

The Testosterone Trials (T-Trials)

The T-Trials, published in the New England England of Medicine in 2016 (N=788 men aged 65 or older with symptomatic hypogonadism), used AndroGel 1% as the study drug. Testosterone gel increased serum testosterone from a mean of 234 ng/dL at baseline to 495 ng/dL at 12 months. Sexual activity improved significantly in the testosterone arm versus placebo (p<0.001). Walking distance improved modestly. Bone mineral density increased at the lumbar spine and femoral neck. [6]

These T-Trials results are frequently cited as evidence for gel efficacy, but they do not include a head-to-head injection arm. Applying T-Trials bone data to injectable testosterone requires caution.

Injection vs. Gel in Comparative Registry Data

A 2017 retrospective study using the MarketScan database (N=11,367 men initiating TRT) found that men on injectable testosterone were 23% more likely to achieve a serum total testosterone above 400 ng/dL at 6 months compared with those on topical gels. However, injectable users also showed a higher rate of erythrocytosis (hematocrit above 52%) at 12 months: 17.8% vs. 9.4% for gel users. [7]

The Endocrine Society 2018 Clinical Practice Guideline states directly: "We suggest that clinicians individualize the choice of testosterone formulation based on patient preference, cost, and potential side effects." [8]

Symptom-Score Outcomes

A 2014 Journal of Sexual Medicine study (N=406) compared patient-reported outcomes on the Androgen Deficiency in Aging Males (ADAM) questionnaire between injection and gel users at 6 months. Both groups showed similar improvements in libido (approximately 65% responder rate in each arm), but injection users reported statistically greater improvements in energy scores (p<0.04). [9]

Real-World Adherence and Persistence

Adherence differs sharply between formulations. This matters because subtherapeutic testosterone levels, not the formulation itself, drive most treatment failures.

Gel Adherence Patterns

A large pharmacy claims analysis published in the American Journal of Men's Health (2016, N=9,427) found that only 41% of men prescribed AndroGel were still filling prescriptions at 12 months. The most common documented reasons for discontinuation were cost (insurance step-therapy requirements), skin irritation at the application site, and inconvenience of daily application. [10]

Injection Adherence Patterns

Self-injection protocols improve persistence. A 2019 study in the Journal of Urology (N=522) found that men trained to self-administer subcutaneous testosterone cypionate had a 12-month persistence rate of 74%, significantly higher than the gel group in the same practice cohort (p<0.001). [11]

Needle phobia remains a real barrier. Roughly 15% of patients offered self-injection in a urology clinic declined within the first three months, per that same 2019 dataset.

Safety Profile Comparison

Erythrocytosis Risk

Testosterone-induced erythrocytosis (hematocrit above 54%) is more common with injections than with gels. The Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after initiation and annually thereafter, with dose reduction or phlebotomy if hematocrit exceeds 54%. [8] The 2017 MarketScan analysis found an erythrocytosis rate of 17.8% with injections versus 9.4% with gel at 12 months. [7]

Secondary Transfer (Gel Only)

The FDA added a black-box warning to all testosterone gel products in 2009 after case reports of virilization in children who had skin-to-skin contact with treated adults. [5] Patients applying AndroGel must wash hands thoroughly, cover the application site with clothing, and avoid skin contact with children or pregnant women until the gel has fully dried.

Injection Site Reactions

Testosterone cypionate injections carry a low but real risk of injection-site pain, oil embolism (extremely rare), and localized infection. Subcutaneous injection, now commonly used off-label at doses of 50 to 70 mg weekly, reduces injection-site induration compared with the traditional intramuscular gluteal route. A 2021 clinical letter in Urology reported that switching 87 patients from intramuscular to subcutaneous cypionate reduced injection-site pain scores by 40% on a 10-point visual analog scale. [12]

Cardiovascular Considerations

Both formulations carry an FDA-required labeling statement about possible increased cardiovascular risk in men with pre-existing disease. The TRAVERSE trial (N=5,246, published NEJM 2023) found that testosterone replacement did not significantly increase major adverse cardiovascular events (MACE) in men with hypogonadism and elevated cardiovascular risk (hazard ratio 0.96, 95% CI 0.78 to 1.17). TRAVERSE used a topical gel formulation. [13] Whether those findings translate directly to injectable testosterone is an open research question.

Cost and Access

Price is often the deciding factor for uninsured or underinsured patients.

Generic Testosterone Cypionate Cost

Generic testosterone cypionate 200 mg/mL (10 mL multi-dose vial) retails for USD 30 to 80 at most pharmacies and is widely available through telehealth prescribers. Syringes, needles, and alcohol swabs add roughly USD 10 to 15 per month. Total monthly cost: approximately USD 45 to 95.

AndroGel Cost

Brand-name AndroGel 1.62% retails at USD 400 to 600 per month without insurance. Generic testosterone gel 1% is available at some pharmacies for USD 60 to 120 per month, though supply varies by region. Patients with commercial insurance frequently face step-therapy requirements that mandate trial of a generic before AndroGel is approved. [14]

Switching From Testosterone Cypionate to AndroGel

Switching is clinically common. Patients may request it to avoid injections, eliminate erythrocytosis risk, or improve convenience. The transition requires attention to timing, dosing, and re-testing.

HealthRX Clinical Switching Framework

The following stepwise protocol reflects current Endocrine Society guidance and common clinical practice. It is not a substitute for individualized physician assessment.

Step 1. Confirm indication for switching. Document the clinical reason (e.g., erythrocytosis, needle phobia, patient preference). Check hematocrit and current serum total testosterone before the last injection.

Step 2. Time the transition. Administer the last cypionate injection on schedule. Begin AndroGel on day 7 after the final injection (the trough window), starting at the labeled dose of 40.5 mg daily (1.62% formulation) or 50 mg daily (1% formulation).

Step 3. Recheck serum testosterone. Draw a morning total testosterone 14 to 28 days after starting the gel to confirm levels are within the 400 to 700 ng/dL target range. Titrate the gel dose by one pump (20.25 mg) up or down as needed per FDA labeling. [5]

Step 4. Monitor hematocrit. Recheck at 6 weeks post-switch. Erythrocytosis often resolves within 8 to 12 weeks of switching from injection to gel, per a 2018 case series in Andrology (N=34). [15]

Step 5. Assess symptoms at 60 days. Because gel produces lower peak testosterone than cypionate injections, some patients report transient fatigue or reduced libido during the adjustment period. Document ADAM or AMS scores at baseline and at 60 days.

Switching From AndroGel to Testosterone Cypionate

This direction is less studied but clinically straightforward. Stop the gel and begin cypionate at 100 mg intramuscularly or subcutaneously every 7 days. Check serum testosterone at day 21 (trough, pre-injection). Adjust to 150 or 200 mg if trough remains below 350 ng/dL. Monitor hematocrit at 6 and 12 weeks, as erythrocytosis risk rises after switching to injection. [8]

Monitoring Requirements for Both Formulations

Both formulations require the same core monitoring parameters per the Endocrine Society 2018 Clinical Practice Guideline. [8]

Labs and Timing

Check serum total testosterone (and free testosterone if total is borderline), hematocrit, prostate-specific antigen (PSA), and lipid panel at baseline, then at 3 to 6 months after initiation or any dose change, and annually once stable. Digital rectal exam is recommended at baseline and at 12 months for men over 40.

Formulation-Specific Monitoring

For gel users, confirm serum testosterone is drawn 2 to 8 hours after application to capture the absorption peak. For injection users, draw the sample at trough (day 7 for weekly dosing, day 14 for biweekly dosing) to ensure the lowest level stays above 300 ng/dL. [8]

A 2022 paper in the Journal of Clinical Endocrinology and Metabolism (N=1,114) found that 38% of clinicians were drawing testosterone labs at non-standardized times relative to dosing, leading to either overtreatment or undertreatment. Standardizing the draw window reduced unnecessary dose changes by 21% in that cohort. [16]

Who Is Each Formulation Best Suited For?

No single formulation fits every patient. The table below summarizes the key differentiators.

| Factor | Testosterone Cypionate | AndroGel | |---|---|---| | Dosing frequency | Every 7 to 14 days (injection) | Daily (topical) | | Serum T stability | Moderate to low (peaks and troughs) | High (stable daily levels) | | Erythrocytosis risk | Higher (17.8% at 12 months) | Lower (9.4% at 12 months) | | Secondary transfer risk | None | Yes (FDA black-box warning) | | Monthly cost (uninsured) | USD 45 to 95 | USD 60 to 600 | | 12-month persistence | ~74% (self-injection) | ~41% | | Best candidate | Patients comfortable with injections, cost-sensitive, those with higher target T levels needed | Patients with needle phobia, lower erythrocytosis risk needed, no household transfer concerns |

Cypionate Is Likely the Better Starting Point When...

The patient is cost-sensitive, comfortable with self-injection or willing to be trained, and does not live with young children or pregnant partners. Men who need consistent high-normal testosterone levels (above 500 ng/dL at trough) are less likely to achieve that with gel monotherapy at standard doses, per the 2017 MarketScan comparative analysis. [7]

AndroGel Is Likely the Better Starting Point When...

The patient has a documented needle phobia, a history of erythrocytosis on prior injectable therapy, or a strong preference for daily routine. Patients with cardiovascular risk who require the most direct evidence of safety may also prefer gel, given that TRAVERSE used a topical formulation. [13]

Fertility Preservation Considerations

Both testosterone cypionate and AndroGel suppress the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH secretion and suppressing endogenous testosterone and spermatogenesis. Neither formulation is appropriate for men actively trying to conceive. [17]

The American Urological Association 2018 Guideline on Male Infertility advises against exogenous testosterone in men who wish to preserve fertility. [17] Men in this category should discuss alternative options such as clomiphene citrate, human chorionic gonadotropin (hCG), or anastrozole, depending on the underlying cause of hypogonadism.

Sperm banking before initiating any testosterone therapy is advisable for men who may want future fertility options. Recovery of spermatogenesis after stopping exogenous testosterone takes a median of 3 to 6 months but may exceed 24 months in some cases. [18]

Practical Clinical Pearls

A few points that do not fit neatly into any single section above deserve direct mention.

Subcutaneous vs. Intramuscular cypionate. The subcutaneous route (25 to 27 gauge, 5/8-inch needle into abdominal fat or lateral thigh) is now widely used off-label. A 2017 study in the Journal of Urology (N=148) found bioequivalent serum testosterone levels between subcutaneous and intramuscular routes at identical doses, with significantly less injection-site discomfort. [19]

Dihydrotestosterone (DHT) and gel. Transdermal testosterone produces higher DHT-to-testosterone ratios than injection. A 2004 pharmacokinetic study in JCEM found DHT levels were 2.4-fold higher with gel versus injection at equivalent serum testosterone targets. [20] The clinical significance of elevated DHT on prostate health remains debated, but men with borderline PSA elevation at baseline may warrant closer monitoring on gel therapy.

Application site and absorption variability. Scrotal application of testosterone gel (off-label) produces dramatically higher DHT due to high 5-alpha-reductase activity in scrotal skin. Standard AndroGel labeling specifies shoulder, upper arm, or abdomen only. Patients should not apply to the scrotum unless using a formulation specifically designed for that site. [5]

The CDC notes that hypogonadism affects an estimated 2 to 6% of men under 40 and rises to 20 to 30% in men over 70, underscoring the breadth of clinical need for evidence-based formulation selection. [21]